{"entity":{"id":"nct07678957","kind":"trial","name":"A Study Comparing BL-M07D1 With DS-8201 in Patients With HR-Positive, HER2-Low Expressing Recurrent/Metastatic Breast Cancer","aka":[],"tldr":"A phase 2 trial of BL-M07D1 in HER2-positive breast cancer and HR-positive / HER2-negative breast cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.","summary":"A Study Comparing BL-M07D1 With DS-8201 in Patients With HR-Positive, HER2-Low Expressing Recurrent/Metastatic Breast Cancer is a phase 2 interventional study registered as NCT07678957 by Sichuan Baili Pharmaceutical Co., Ltd., with 120 participants planned, started 2026-08-31 and due to reach its primary completion in 2028-12. Interventions recorded: BL-M07D1 and DS-8201.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07678957","url":"https://clinicaltrials.gov/study/NCT07678957"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["breast-her2-positive","breast-hr-positive","her2-low-metastatic-breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["systimmune"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07678957","phase":"2","setting":"A Randomized Controlled Phase II Clinical Study Comparing BL-M07D1 With DS-8201 in Patients With HR-Positive, HER2-Low Expressing Recurrent/Metastatic Breast Cancer","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","participation":[{"nct":"NCT07678957","source":"https://clinicaltrials.gov/study/NCT07678957","fetchedAt":"2026-10-07T16:55:56.330Z","studySha256":"e04e90ba142bdd5e334a4a559f25f155a2cf40cf84950a2ee9a380551416b801","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-14","leadSponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","collaboratorCount":1,"minimumAge":"18 Years","maximumAge":"75 Years","sex":"FEMALE","healthyVolunteers":false,"hasEligibility":true,"enrolment":120,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2026-08-31","startedType":"actual","enrolled":120,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07678957/","neighbours":{"cancer":[{"id":"her2-low-metastatic-breast-cancer","kind":"cancer","name":"HER2-low and HER2-ultralow metastatic breast cancer","route":"/cancers/her2-low-metastatic-breast-cancer/"},{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"company":[{"id":"systimmune","kind":"company","name":"SystImmune / Sichuan Biokin","route":"/companies/systimmune/"}]}}